Table 1.
Baseline clinical characteristics of patients
| Patient ID | Sex | Age | Pathology | ECOG PS | Driver genes | Prior antitumor treatment | First-line treatment | Second-line treatment | Third-line treatment | PD-L1 TPS | Treatment cycle |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P01 | M | 67 | A | 0 | WT | Sur + C | Sur |
bone metastasis C:AP |
C: docetaxel | 1 | 10 |
| P02 | F | 64 | S | 0 | EGFR exon19Del | T + C | T: gefitinib |
brain metastasis T: Axitinib |
C:AP | 0 | 4 |
| P03 | M | 73 | S | 1 | WT | Sur + C | Sur |
lung metastasis C:TP |
bone metastasis C: docetaxel |
5 | 6 |
| P04 | F | 41 | S | 1 | WT | C + R + An | C:TP |
bone metastasis:R C: docetaxel |
An | 0 | 9 |
| P06 | F | 56 | A | 0 | WT | C | C:AP | C: GP | C: docetaxel | 20 | 12 |
| P08 | M | 63 | A | 1 | EGFR exon19Del、TP53 | T + C | T: gefitinib |
brain metastasis T: Axitinib |
C:AP | 0 | 3 |
| P09 | M | 44 | A | 0 | WT | C + B | C:AP | C + B: B + AP | C + B: B + docetaxel | 15 | 12 |
| P11 | M | 61 | A | 1 | WT | C + B + An | C:AP | C + B: B + AP | An | 5 | 4 |
| P13 | M | 39 | A | 0 | WT | C + B | C:AP | C + B: B + AP | C + B: B + docetaxel | 0 | 9 |
| P14 | M | 58 | S | 1 | WT | C + An | C:TP | C: docetaxel | An | 40 | 9 |
| P16 | F | 63 | S | 1 | WT | C + R + An | C:TP |
brain metastasis:R C: docetaxel |
An | 55 | 3 |
| P17 | M | 60 | A | 1 | EGFR L858R | T + C | T: gefitinib | T: Axitinib | C:AP regimen | 2 | 6 |
| P21 | M | 67 | A | 2 | WT | C + B + An | C:AP | B + C:B + AP | An | 0 | 3 |
M: male, F: female, A: adenocarcinoma, S: squamous cell carcinoma, ECOG PS: Eastern cooperative oncology Group performance status, WT: wild-type, EGFR: epidermal growth factor receptor, Sur: surgery, C: Chemotherapy, R: Radiotherapy, B: Bevacizumab, An: Anlotinib, T: targeted therapy, AP: Pemetrexed plus Cisplatin, TP: Paclitaxel plus Cisplatin, GP: Gemcitabine plus Cisplatin